TECENTRIQ Drug Profile

Summary for Tradename: TECENTRIQ

High Confidence Patents:	19
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TECENTRIQ

Recent Clinical Trials for TECENTRIQ

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University Health Network, Toronto	PHASE1
Christine Ryan	Phase 2
Jun Zhang, MD, PhD	Phase 2

See all TECENTRIQ clinical trials

Pharmacology for TECENTRIQ

Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Programmed Death Receptor-1 Blocking Antibody
Chemical Structure	Antibodies Antibodies, Monoclonal Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TECENTRIQ Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TECENTRIQ Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-05-12	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-08-18	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2035-04-17	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-05-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for TECENTRIQ Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-06-24	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2038-06-01	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2038-06-01	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2037-04-06	Patent claims search

International Patents for TECENTRIQ

Country	Patent Number	Estimated Expiration
Israel	278007
Taiwan	202417499
Hungary	S2400018
Portugal	1537878

Supplementary Protection Certificates for TECENTRIQ

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
LUC00345	Luxembourg		PRODUCT NAME: ATEZOLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1220 20170925
2016C/001	Belgium		PRODUCT NAME: KEYTRUDA (PEMBROLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/15/1024 20150721
122025000023	Germany		PRODUCT NAME: ATEZOLIZUMAB; REGISTRATION NO/DATE: EU/1/17/1220 20170921
C20240020	Finland

Market Dynamics and Financial Trajectory for TECENTRIQ (Atezolizumab)

Last updated: March 5, 2026

What is TECENTRIQ and How Has It Entered the Market?

TECENTRIQ (atezolizumab) is a PD-L1 immune checkpoint inhibitor developed by Roche. Approved in 2016, it targets several cancer types, including metastatic urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and small cell lung cancer (SCLC). Its global approval covers over 60 countries, with major markets including the U.S., EU, and China.

How Does TECENTRIQ Compare to Similar Biologics?

Drug Name	Target	Approved Indications	Launch Year	Estimated Global Sales (2022)	Market Share in PD-1/PD-L1 Space (2022)
TECENTRIQ	PD-L1	NSCLC, SCLC, Urothelial Carcinoma, Breast, Others	2016	$1.97 billion	12%
Keytruda	PD-1	Lung, Melanoma, Kidney, Bladder, Others	2014	$21.40 billion	60%
Opdivo	PD-1	Lung, Head & Neck, Kidney, Others	2015	$6.56 billion	20%

TECENTRIQ occupies a secondary position, mainly driven by its effectiveness in specific niches like urothelial cancer. Its sales are lower than competitors like Merck's Keytruda but surpass other PD-L1 inhibitors such as Bavencio.

What Are the Main Market Drivers Influencing TECENTRIQ?

• Expanding Approved Indications: Continued trials aim to broaden TECENTRIQ's label, including metastatic triple-negative breast cancer and other solid tumors.
• Biomarker Development: PD-L1 expression as a biomarker guides patient selection, influencing treatment efficacy and market penetration.
• Combination Therapies: Combining TECENTRIQ with chemotherapy (e.g., IMpassion130 trial for breast cancer) enhances efficacy, expanding use cases.
• Regulatory Approvals in Emerging Markets: China, India, and Brazil approve TECENTRIQ in fewer indications but present significant growth opportunities due to rising cancer incidence.
• Competitive Landscape: Keytruda's dominance limits TECENTRIQ's market share, though Roche's focus on niche indications and combination strategies mitigates this.

How Has Revenue Evolved Over Recent Years?

Year	Estimated Global Sales (USD)	Growth Rate (Compared to Previous Year)
2018	~$600 million	50%
2019	~$900 million	50%
2020	$1.50 billion	66%
2021	$1.75 billion	17%
2022	$1.97 billion	12%

Sales growth peaked in 2020, driven by increased approvals and expanding indications. Post-2020 growth slowed, partly due to market saturation and stiff competition.

What Are the Financial Projections for TECENTRIQ?

Analysts project TECENTRIQ's global sales to reach approximately $2.4 billion in 2025, contingent upon:

• Approval of new indications (e.g., first-line lung cancer)
• Successful trials in additional tumor types
• Expanded use in combination therapies
• Growth in emerging markets

Roche's strategic focus on collaboration and biomarker-driven funding aims to sustain revenue growth despite competitive pressure.

What Market Challenges and Opportunities Face TECENTRIQ?

Challenges:

• Intense Competition: Keytruda maintains dominant market share through broad indications and strong clinical data.
• Market Saturation: Limited room for growth in existing approved indications.
• Pricing & Reimbursement: Cost pressures in Western markets influence profit margins.
• Pipeline Risks: Unsuccessful trials could limit future approvals or expansion.

Opportunities:

• Pipeline Expansion: Ongoing trials in lung, prostate, and other solid tumors could enhance indication portfolio.
• Combination Strategies: Synergistic combinations with targeted therapies, chemotherapy, or other immuno-oncology agents.
• Biomarker Refinement: Enhanced patient selection models could improve outcomes and justify premium pricing.
• Emerging Markets: Growth potential in Asia and Latin America, where cancer prevalence is rising, and access is increasing.

What Are the Key Takeaways?

• TECENTRIQ generated nearly $2 billion in sales in 2022.
• It competes mainly with Keytruda and Opdivo, holding a secondary market position.
• Growth is driven by new approvals and combination therapies, yet faces hurdles from market saturation and price pressures.
• Analysts expect sales to reach approximately $2.4 billion by 2025, assuming favorable regulatory and clinical outcomes.
• The drug’s future hinges on pipeline success, indication expansion, and emerging market penetration.

FAQs

1. What are TECENTRIQ's primary approved indications?
   Metastatic urothelial carcinoma, non-small cell lung cancer (first-line and second-line), small cell lung cancer, and triple-negative breast cancer.

2. How does TECENTRIQ's efficacy compare to Keytruda?
   Efficacy depends on tumor type and biomarker expression; Keytruda generally demonstrates broader approval and higher market share, but TECENTRIQ shows competitive results in specific indications like urothelial carcinoma.

3. Can TECENTRIQ be combined with other therapies?
   Yes. It is used in combination with chemotherapy or other immunotherapies to improve responses, exemplified in trials like IMpassion130.

4. What are the main growth opportunities for TECENTRIQ?
   Expanding indications through clinical trials, combination therapies, and market penetration in emerging economies.

5. What risks could hinder TECENTRIQ’s financial outlook?
   Competitive pressure from competitors’ regulatory approvals, clinical trial failures, pricing controls, and reimbursement policies.

---

References

[1] Roche. (2022). TECENTRIQ (Atezolizumab) prescribing information.
[2] IQVIA. (2022). Oncology market reports.
[3] EvaluatePharma. (2022). World Preview 2023: Outlook to 2028.
[4] FDA. (2016). Approval summaries for TECENTRIQ.
[5] NICE. (2021). TECENTRIQ approval and guidelines.